Close Menu

Sandra Porter says that she was content to avoid microarrays for a long while, with the articles questioning reliability and stories coming out of labs. However, she's had a change of heart. "Then Next Generation DNA Sequencing (NGS) came along. It turned out that many of the data analysis techniques developed for microarrays were useful for analyzing Next Gen data. I couldn't avoid them anymore," Porter writes. "It was time to bite the bullet and learn about microarrays."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.